| Objective: Based on prospective single-center randomized controlled trial, to investigate the clinical efficacy of aidi injection combined with carrelizumab in treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods:A total of 82 patients with advanced NSCLC admitted to our hospital from April 2022 to March 2024 were prospectively selected and divided into control group ( n = 41 ) and study group ( n = 41 ) by random number table method. Control group received conventional chemotherapy and carrelizumab treatment, and study group received aidi injection on the basis of control group. The objective response rate (ORR), disease control rate (DCR), serum tumor markers [cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), squamous cell carcinoma antigen (SCCA), tumor specific growth factor (TSGF)], immune indexes [immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin G (IgG), dendritic cells (DC), DC/mononuclear macrophages (PBMC)], tumor invasion and metastasis indexes [matrix metalloproteinase 1 (MMP-1), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9)] and the total incidence of adverse reactions were compared between two groups. Results: The ORR and DCR in study group were higher than those in control group (P<0.05). The levels of serum CYFRA21-1, TSGF and SCCA in two groups decreased after treatment, and the levels of serum CYFRA21-1, TSGF and SCCA in study group were lower than those in control group (P<0.05). IgM, IgA, IgG, DC and DC/PBMC decreased in both groups after treatment, and IgM, IgA, IgG, DC and DC/PBMC in study group were higher than those in control group (P<0.05). The levels of serum MMP-1, MMP-9 and MMP-2 in two groups decreased after treatment, and the levels of serum MMP-1, MMP-9 and MMP-2 in study group were lower than those in control group (P<0.05). There was no difference in the total incidence of adverse reactions in two groups(P>0.05). Conclusion: Aidi injection combined with carrelizumab in the treatment of advanced NSCLC, which can improve the overall efficacy, effectively regulate the level of serum tumor markers, reduce immunosuppression, prevent tumor invasion and metastasis, and is safe and effective. |
